At Ellele Health, our goal is to advance the next generation of diagnostics and treatments across gynaecological conditions. It’s an ambitious goal - one we know we cannot achieve alone.
We believe in radical collaboration with academics, clinicians and commercial partners who share our commitment to advancing Women’s Health.
Together, we are recouping decades of missed opportunities to improve outcomes across gynaecological conditions.
And the need has never been more urgent.
We know the broad potential the Ellele Sampling Device can have across gynaecological conditions and our ambition is for the whole of Women's Health field to benefit.
to collaborators and partners whose research would benefit from better sampling.
Ellele Health established a partnership with the University of Edinburgh and the Royal Infirmary of Edinburgh in 2024 to advance early detection of endometrial and ovarian cancers. To date, we have conducted the Ellele-01 feasibility study and are in process of running the Ellele-02 exploratory study.
Ellele Health and Predica Diagnostics entered a partnership in 2024 to tackle the diagnosis of high-grade cervical dysplasia. The Ellele Sampling Device was validated against Predica’s HPV Profiler molecular assay, demonstrating superior sampling with the Ellele Sampling Device compared with traditional swabs. Predica Diagnostics and Ellele Health are looking to continue the partnership via mutually funded studies.
Find out more about Predica Diagnostics.
PREDI-Endo is a large nested prospective study involving women with Lynch syndrome (LS) who are at high risk for endometrial and ovarian cancers. As a less invasive, patient-friendly alternative to current standard of care, the Ellele Sampling Device is being evaluated as an alternative method for surveillance of endometrial cancer in women with LS. The study is expected to commence in August 2026.
Find out more about Predi-Lynch Consortium.